13th Annual International Congress on the Future of Breast Cancer®
13th Annual International Congress on the Future of Breast Cancer®Hyatt Regency Huntington Beach
Huntington Beach, CA
July 17-19, 2014
The 13th Annual International Congress on the Future of Breast Cancer®
serves as an update on advances in the breast cancer field with a focus on the clinical implications of breast cancer genetic and phenotypic subtyping. Novel agents, strategies, and improved regimens are changing the future of breast cancer therapy, and these advances and their clinical impact are highlighted throughout the program. Current controversies in the field are also addressed and debated, and new data presented along with information about how to optimally individualize breast cancer therapy. This conference provides a unique opportunity for medical, surgical, and radiation oncologists and other health care professionals to learn from and interact with international leaders in breast cancer in order to increase knowledge, apply new data to practice, and ultimately improve patient outcomes.
This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer may also participate.
Disclosure Policy and Conflict of Interest Resolution
As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).
Additionally, PER® is required by ACCME to resolve all COI. We have identified and resolved all COI prior to the start of this activity by using a multi-step process.
Faculty, Staff, and Planners’ Disclosure
The following individuals have no relevant financial relationships with commercial interests to disclose: Linda Bosserman, MD, FACP
; Jenny Chang, MD
; David Euhus, MD, FACS
; Lori J. Goldstein, MD
; Frankie Ann Holmes, MD, FACP
; Nola M. Hylton, PhD
; Claudine Isaacs, MD
; Seema A. Khan, MD
; Lori J. Pierce, MD, FASTRO
; and Joseph Sparano, MD
The staff of Physicians’ Education Resource®
, LLC: Ann C. Lichti, CCMEP; Susan Peck, PhD; Emily Valko Lohrmann
The following individuals have relevant financial relationships with commercial interests to disclose:
Kathy S. Albain, MD, FACP
– Consultant: Genomic Health Inc; Adam Brufsky, MD, PhD, FACP
— Grant/Research Support: Novartis; Consultant: Novartis; Sara Hurvitz, MD
— Grant/Research Support (paid to institution): Genentech, Roche, Sanofi, GSK, Novartis, Boehringer Ingelheim, OBI Pharmaceuticals, Amgen; Other (travel reimbursement for role as speaker at conferences): Novartis and Boehringer-Ingelheim; Suzanne A. W. Fuqua, PhD
– Grant/Research Support: Janssen; Reshma Jagsi, MD
— Grant/Research Support: AbbVie Pharmaceuticals: (provision of drug/distribution only for a Phase I trial on which she is a PI and for which funding comes from a philanthropic foundation); Medical Advisory Board Member: Eviti; Carol Lange, PhD
— Consultant: ARNO Therapeutics, Inc; Eleftherios Mamounas, MD, MPH, FACS
– Consultant: Genomic Health Inc, Celgene, GE Healthcare, Eisai; Speaker’s Bureau: Genomic Health Inc; Ruth O’Regan, MD
– Grant/Research Support: Genentech, Novartis; Consultant: Novartis; Joyce O’Shaughnessy, MD
- Consultant/Advisory Board Member: Arno Therapeutics, Celgene Corporation, Corcept Therapeutics, Eisai, Genentech, GSK, Johnson & Johnson, Lilly, Med Fusion, LLC, Merrimack, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals, Pfizer, sanofi-aventis; Hope Rugo, MD
– Grant/Research Support: GSK, Genentech/Roche, Novartis, Merck, Pfizer, Amgen, Plexxikon, Macrogenics, Eisai, Celgene; Speaker’s Bureau: Genomic Health; William Sikov, MD
– Consultant: AbbVie (unpaid); Debu Tripathy, MD
– Grant/Research Support: Genentech/Roche, Pfizer, Puma, Inc (clinical trial support contracted to University of California); Consultant: Eisai, Novartis; David E. Wazer, MD, FASTRO
– Consultant: Advanced Radiation Therapy, Inc.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®
, LLC, or any of the companies that provided commercial support for this activity.